Serious Medical Derm: Hot Topics & Clinical Controversies—Derms on Drugs Style

Ready to level up your medical dermatology game? This week, Derms on Drugs tackles the toughest questions and latest controversies in serious derm—served with our signature practical, no-nonsense style with a big dose of humor.We break down the newest literature and answer:Does immunotherapy really help with high-risk squamous cell carcinoma?Are pemphigus patients getting more rituximab than they need?Why don’t JAK inhibitors increase cardiovascular risk in atopic dermatitis?Is the Mind.Px test actually helpful for picking a psoriasis biologic?What does drug level monitoring tell us about adalimumab in hidradenitis suppurativa?Which treatment factors predict scabies cure?Perfect for dermatology providers and industry pros who want clinical pearls, evidence-based answers, and a few laughs along the way. Tune in for the most fun you’ll have while getting smarter about serious medical derm!Hit play and stay on the cutting edge of medical dermatology!1.  Adjuvant Cemiplimab or Placebo in HighRisk Cutaneous Squamous-Cell Carcinoma2.  Efficacy, safety, and B-cell depletion capacity of three rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: a 52-week clinical trial3.  Understanding Cardiovascular Events With JAK Inhibitors: Tofacitinib Reduces Synovial and Vascular Inflammation but not the Prothrombotic Effects of Inflammatory Cytokines on Endothelium4.  Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis5.  Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes6.  Therapeutic Drug Monitoring in Hidradenitis Suppurativa Patients With Suboptimal Treatment Response to Adalimumab7.  Scabies Management Outcomes: Identification of Risk Factors for Treatment Success or Failure